Literature DB >> 10929927

Is there a growing role for endocrine therapy in the treatment of breast cancer?

P E Lønning1.   

Abstract

Novel biochemical findings on the molecular mechanisms of estrogen actions may help us to understand some of the unexplained observations seen in breast cancer treatment and suggest new therapeutic opportunities. Thus, apart from the challenge of improving the clinical treatment of patients with advanced disease, results from trials in this setting may reveal new therapeutic principles that may be evaluated in the adjuvant setting. The role of endocrine therapy in metastatic as well as early breast cancer is increasing, and the possibility of improving cure rates for breast cancer by implementing therapy with novel aromatase inhibitors in the adjuvant setting is exciting. While the results from prevention trials are most interesting, suggesting the possibility of reducing breast cancer incidence in high-risk groups, more data are needed before we can decide whether such interventions are warranted in women at high risk of developing breast cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10929927     DOI: 10.2165/00003495-200060010-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  94 in total

1.  The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.

Authors:  Q Lu; Y Liu; B J Long; D Grigoryev; M Gimbel; A Brodie
Journal:  Breast Cancer Res Treat       Date:  1999-09       Impact factor: 4.872

2.  ER beta: identification and characterization of a novel human estrogen receptor.

Authors:  S Mosselman; J Polman; R Dijkema
Journal:  FEBS Lett       Date:  1996-08-19       Impact factor: 4.124

3.  Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.

Authors:  C Harper-Wynne; R C Coombes
Journal:  Eur J Cancer       Date:  1999-05       Impact factor: 9.162

4.  Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

Authors:  M Kaufmann; E Bajetta; L Y Dirix; L E Fein; S E Jones; N Zilembo; J L Dugardyn; C Nasurdi; R G Mennel; J Cervek; C Fowst; A Polli; E di Salle; A Arkhipov; G Piscitelli; L L Miller; G Massimini
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

Authors:  R Cash; A J Brough; M N Cohen; P S Satoh
Journal:  J Clin Endocrinol Metab       Date:  1967-09       Impact factor: 5.958

6.  A randomized trial on tamoxifen continuation during second-line hormone therapy in breast cancer.

Authors:  P Pronzato; G Bertelli; M Rosso
Journal:  Ann N Y Acad Sci       Date:  1993-11-30       Impact factor: 5.691

7.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

8.  Steroid-hormone receptors and survival after first relapse in breast cancer.

Authors:  A Howell; D M Barnes; R N Harland; J Redford; V H Bramwell; M J Wilkinson; R Swindell; D Crowther; R A Sellwood
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

Review 9.  Progestins in breast cancer treatment. A review.

Authors:  S Lundgren
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

10.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

Authors:  U Veronesi; P Maisonneuve; A Costa; V Sacchini; C Maltoni; C Robertson; N Rotmensz; P Boyle
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more
  1 in total

Review 1.  Exemestane: a review of its use in postmenopausal women with breast cancer.

Authors:  Emma D Deeks; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.